TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2470000

Group type: EXPERIMENTAL
Intervention: COP-BLAM (5 courses)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: IMVP-16 (2 courses)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Overall treatment strategy
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Dose reductions and interval prolongations
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Relapses
Number of subjects: 349
Study: 1096275

Group type: EXPERIMENTAL
Intervention: Prenazone 600 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin 4 g daily
Number of subjects: 20
Study: 31076856

Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (folic acid 400 µg and vitamin B12 500 µg)
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 2919
Study: 30173939

Group type: EXPERIMENTAL
Intervention: Tai Chi with music
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 29980493

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27828579

Group type: EXPERIMENTAL
Intervention: Cognitive-motor physiotherapy intervention (4 months, single weekly visit)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study: 25104582

Group type: EXPERIMENTAL
Intervention: 3g of sea buckthorn (SB) oil daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 116
Study: 23082956

Group type: EXPERIMENTAL
Intervention: Moderate sodium intake (180 mmol/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low sodium intake (60 mmol/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 19681738

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 30 minutes, five days per week, for eight weeks.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual activities with no specific exercise (Control group).
Number of subjects: 44
Study: 17963431

Group type: EXPERIMENTAL
Intervention: MN 001 (750 mg twice daily)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: MN 001 (500 mg three times daily)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study: 15114532

Group type: EXPERIMENTAL
Intervention: HbE variant
Number of subjects: 0
Study: 11449671

Group type: EXPERIMENTAL
Intervention: Intravenous administration of argatroban (10 mg/day, three times a week)
Number of subjects: 55
Study: 9482129

Group type: EXPERIMENTAL
Intervention: verapamil SR 240 mg (V)
Number of subjects: 26

Group type: COMPARATOR
Intervention: amiloride 5 mg + hydrochlorothiazide 50 mg (AH)
Number of subjects: 26
Study: 8304488

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion to maintain plasma ANG II levels at around basal values (6.6 ± 1.6 pmol/l)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Infusion of aldosterone (previous study)
Number of subjects: 8
Study: 2541981

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (PGA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Polyester
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (PGA) in men
Number of subjects: 300

Group type: COMPARATOR
Intervention: Polyester in men
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (PGA) with risk factors (obesity, bronchitis, recurrent hernia, size of hernial sac > 8 cm)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Polyester with risk factors (obesity, bronchitis, recurrent hernia, size of hernial sac > 8 cm)
Number of subjects: 300
Study: 29973241

Group type: EXPERIMENTAL
Intervention: Support for traditional midwives including a small stipend, a scholarship to train one apprentice, and support from an intercultural broker; workshops for health staff in intervention municipalities.
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Support for traditional midwives
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8000
Study: 27098638

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both phases
Number of subjects: 48
Study: 25677736

Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 48
Study: 25104262

Group type: EXPERIMENTAL
Intervention: Abbreviated counselling
Number of subjects: 3415

Group type: COMPARATOR
Intervention: Traditional counselling
Number of subjects: 3415

Group type: EXPERIMENTAL
Intervention: Enhanced linkage to care
Number of subjects: 3415

Group type: COMPARATOR
Intervention: Standard linkage to care
Number of subjects: 3415
Study: 20507844

Group type: EXPERIMENTAL
Intervention: Prosdex online decision aid
Number of subjects: 82
Study: 18237592

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 271

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 271
Study: 16617228

Group type: EXPERIMENTAL
Intervention: Regular walking
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care (irregular walkers)
Number of subjects: 123
Study: 12356658

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 10077777

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg b.i.d. for 10 days)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg b.i.d. for 10 days)
Number of subjects: 501
Study: 7586944

Group type: EXPERIMENTAL
Intervention: Buccal administration of 5 mg atipamezole hydrochloride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Buccal administration of 10 mg atipamezole hydrochloride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Buccal administration of 20 mg atipamezole hydrochloride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Buccal administration of 40 mg atipamezole hydrochloride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 20 mg atipamezole hydrochloride
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral administration of 20 mg atipamezole hydrochloride
Number of subjects: 15
Study: 2181789

Group type: EXPERIMENTAL
Intervention: YAL-irrigation
Number of subjects: 60

Group type: COMPARATOR
Intervention: PEG (polyethylene glycol electrolyte)
Number of subjects: 60
Study: 36449

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prone positioning with abdomen protruding freely
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prone positioning with abdomen restricted
Number of subjects: 14
Study: 31838561

Group type: EXPERIMENTAL
Intervention: Oral-VRL (60 mg/m2 for cycle 1, 80 mg/m2 for cycles 2-6) + EPI (75 mg/m2 on day 1 for all cycles)
Number of subjects: 133

Group type: COMPARATOR
Intervention: IV-VRL (25 mg/m2 for cycle 1, 30 mg/m2 for cycles 2-6) + EPI (75 mg/m2 on day 1 for all cycles)
Number of subjects: 133
Study: 28736942

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 0
Study: 27044546

Group type: EXPERIMENTAL
Intervention: Clarithromycin at 1 g daily for three consecutive days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 25540273

Group type: EXPERIMENTAL
Intervention: HPV-16/HPV-18 AS04-adjuvanted vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 0
Study: 23788532

Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 255
Study: 20529982

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 100

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 100
Study: 18927461

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 6483

Group type: COMPARATOR
Intervention: Pooled RCTs
Number of subjects: 6483
Study: 16600938

Group type: EXPERIMENTAL
Intervention: High energy density complementary foods (1.5 kcal/g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low energy density complementary foods (0.4 kcal/g)
Number of subjects: 10
Study: 12760701

Group type: EXPERIMENTAL
Intervention: Syntac Single‐Component with Heliomolar resin composite to dried dentin rewet with Protect
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Syntac Single‐Component with Heliomolar resin composite to dried dentin rewet with HurriSeal
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Syntac Single‐Component with Heliomolar resin composite to dry dentin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Syntac Single‐Component with Heliomolar resin composite to moist dentin (control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus with Point 4 resin composite to dried dentin rewet with Protect
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus with Point 4 resin composite to dry dentin
Number of subjects: 180

Group type: COMPARATOR
Intervention: OptiBond Solo Plus with Point 4 resin composite to moist dentin (control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus with Point 4 resin composite to dried dentin rewet with HurriSeal
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT with TPH Spectrum resin composite to dried dentin rewet with Protect
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT with TPH Spectrum resin composite to dry dentin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Prime & Bond NT with TPH Spectrum resin composite to moist dentin (control)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT with TPH Spectrum resin composite to dried dentin rewet with HurriSeal
Number of subjects: 180
Study: 10807483

Group type: EXPERIMENTAL
Intervention: Titrated RUL ECT at 2.25 times initial seizure threshold (mean dose, 136 mC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fixed dose RUL ECT at 403 mC
Number of subjects: 72
Study: 9264420

Group type: EXPERIMENTAL
Intervention: lovastatin (20 mg/day)
Number of subjects: 6605

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6605
Study: 8099492

Group type: EXPERIMENTAL
Intervention: alpha 1‐adrenergic blocker doxazosin (2 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 2893448

Group type: EXPERIMENTAL
Intervention: Synthetic secretin (0.5 CU/kg/h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Somatostatin (3.5 micrograms/kg/h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31702415

Group type: EXPERIMENTAL
Intervention: Web-based, tailored intervention (Puff City)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic web-based asthma education (control)
Number of subjects: 0
Study: 28758531

Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed amniotomy
Number of subjects: 150
Study: 27563680

Group type: EXPERIMENTAL
Intervention: 3-month, 6-session diabetes-related social support groups (SSG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 3-month diabetes self-management education intervention (DSME)
Number of subjects: 47
Study: 24531309

Group type: EXPERIMENTAL
Intervention: Nobori biolimus-eluting stent (N-BES)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 120
Study: 22614285

Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid (HA) 800 mg and chondroitin sulfate (CS) 1 g in 50 mL of saline solution once weekly for 4 weeks then once every 2 weeks twice more (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Long term antibiotic prophylaxis using sulfamethoxazole 200 mg and trimethoprim 40 mg once weekly for 6 weeks (group 2; control)
Number of subjects: 28
Study: 20153690

Group type: EXPERIMENTAL
Intervention: Glutamate (D2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Capsaicin (B2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isotonic saline (C2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glutamate (A2)
Number of subjects: 15
Study: 18713150

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinse, 0.2% CHX digluconate, three times a day for 7 days before TTBPE removal
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no antimicrobial treatment)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouth rinse
Number of subjects: 51
Study: 16463767

Group type: EXPERIMENTAL
Intervention: Dix-Hallpike maneuver
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Side-lying maneuver
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Roll test
Number of subjects: 72
Study: 11752105

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.01-1.0 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Edrophonium (0.2-0.4 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Edrophonium (1.0 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 25
Study: 9676891

Group type: EXPERIMENTAL
Intervention: 150 microg/kg dynorphin A (1-13)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 1000 microg/kg dynorphin A (1-13)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 500 microg/kg dynorphin A (1-13)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 8004311

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 10
Study: 2512372

Group type: EXPERIMENTAL
Intervention: Knee-chest position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Supine position (Control)
Number of subjects: 15
Study: 804397

Group type: EXPERIMENTAL
Intervention: Parenteral carbohydrates combined with essential amino acids and histidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water and electrolyte balance
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 24
Study: 6782862

Group type: EXPERIMENTAL
Intervention: Cimetidine b.i.d.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31610033

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 47
Study: 29037630

Group type: EXPERIMENTAL
Intervention: High velocity low amplitude technique (HVLA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cervical Lateral glide mobilization (CLGM)
Number of subjects: 75
Study: 25732915

Group type: EXPERIMENTAL
Intervention: Patient-matched instrument system (PMI)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard TKA surgical instrumentation (STD)
Number of subjects: 38
Study: 23398227

Group type: EXPERIMENTAL
Intervention: Nicotine gum treatment
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 194
Study: 21491990

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) chips
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo chips
Number of subjects: 24
Study: 19722727

Group type: EXPERIMENTAL
Intervention: Absolute frequency format
Number of subjects: 187

Group type: COMPARATOR
Intervention: Verbal format
Number of subjects: 187

Group type: COMPARATOR
Intervention: Combined format
Number of subjects: 187
Study: 17188609

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT) and low FPIR
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Baseline factors (BMI, FPIR, 2-hour glucose)
Number of subjects: 711
Study: 14767260

Group type: EXPERIMENTAL
Intervention: Exercise group (3 to 4 times per week at 50% of VO2max expending 4 kcal/kg/week)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Exercise group (3 to 4 times per week at 50% of VO2max expending 8 kcal/kg/week)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Exercise group (3 to 4 times per week at 50% of VO2max expending 12 kcal/kg/week)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 450
Study: 12023757

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) implant
Number of subjects: 200

Group type: COMPARATOR
Intervention: Titanium cage
Number of subjects: 200
Study: 9855418

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines
Number of subjects: 2497

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2497
Study: 8011010

Group type: EXPERIMENTAL
Intervention: Ketorolac (10 mg every 6 h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg every 8 h)
Number of subjects: 100
Study: 2492166

Group type: EXPERIMENTAL
Intervention: Human growth hormone‐releasing factor (GH‐RF) (1 microgram/kg i.v.)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 1096540

Group type: EXPERIMENTAL
Intervention: 80 mg per day of temazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31055542

Group type: EXPERIMENTAL
Intervention: Pranayama breathing exercises for 15 minutes daily for 1 month
Number of subjects: 70

Group type: COMPARATOR
Intervention: MyCalmBeat portable device
Number of subjects: 70
Study: 27682437

Group type: EXPERIMENTAL
Intervention: Weekday sunlight exposure
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Dietary vitamin D intake
Number of subjects: 1312
Study: 25331972

Group type: EXPERIMENTAL
Intervention: Dirksen stomach tube
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Geishauser stomach tube
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tube 4
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Simple water hose used with a gag
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5
Study: 23834229

Group type: EXPERIMENTAL
Intervention: 10% w/v chlorhexidine varnish coating
Number of subjects: 983

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 983
Study: 21670470

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fludarabine, cyclophosphamide, and rituximab (as salvage therapy)
Number of subjects: 80
Study: 19751458

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 301

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 301

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 301

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 301
Study: 18198776

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tenoxicam 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral tenoxicam 20 mg a day for 10 days
Number of subjects: 30
Study: 15051552

Group type: EXPERIMENTAL
Intervention: Ginger (1.05 g daily for 3 weeks)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Vitamin B6 (75 mg daily for 3 weeks)
Number of subjects: 291
Study: 11996757

Group type: EXPERIMENTAL
Intervention: Participation in clinical trials (CT) for essential hypertension
Number of subjects: 73
Study: 9690699

Group type: EXPERIMENTAL
Intervention: Flutamide (a selective androgen receptor antagonist)
Number of subjects: 13
Study: 7516637

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) 100 mg/mq i.v. on day 1 and 5-fluorouracil (5-FU) 750 mg/mq/day i.v. continuous infusion from days 1 to 4
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cisplatin (DDP) 100 mg/mq i.v. on day 1 and 5-fluorouracil (5-FU) 750 mg/mq/day i.v. continuous infusion from days 1 to 4 with added alpha interferon (IFN-alpha) 3 MU s.c., three times weekly from days 1 to 21
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) and 5-fluorouracil (5-FU) with recombinant granulocyte colony stimulating factor (G-CSF) 5 micrograms/kg b.w. s.c. from days 7 to 18
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cisplatin (DDP), 5-fluorouracil (5-FU), and alpha interferon (IFN-alpha)
Number of subjects: 20
Study: 2815647

Group type: EXPERIMENTAL
Intervention: Millimetric waves treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study: 791351

Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (Partusisten) aerosol, 5 puffs of 200 mug each
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 5
Study: 31888702

Group type: EXPERIMENTAL
Intervention: Buzhong Yiqi decoction plus standard therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 200
Study: 28432842

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Quinolinic acid (QUIN)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Kynurenine
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 136
Study: 25963758

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate with single dose of calcium gluconate (SBCG1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate with double dose of calcium gluconate (SBCG2)
Number of subjects: 74
Study: 22875194

Group type: EXPERIMENTAL
Intervention: MIDFOOT
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: COMBI
Number of subjects: 9

Group type: COMPARATOR
Intervention: NORM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: RACE
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FREQ
Number of subjects: 9
Study: 21353124

Group type: EXPERIMENTAL
Intervention: Family practice-based depression case management
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study: 18565520

Group type: EXPERIMENTAL
Intervention: Genuine foot reflexology
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham reflexology
Number of subjects: 48
Study: 16642484

Group type: EXPERIMENTAL
Intervention: Treatment at IMIP (Recife, Brazil)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Treatment at US centers
Number of subjects: 433